These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 32691140)

  • 21. The clinical profile of benralizumab in the management of severe eosinophilic asthma.
    Menzella F; Lusuardi M; Galeone C; Facciolongo N; Zucchi L
    Ther Adv Respir Dis; 2016 Dec; 10(6):534-548. PubMed ID: 27612492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of eosinophilic chronic rhinosinusitis in switching to benralizumab treatment in mepolizumab responders.
    Hamada S; Kobayashi Y; Yasuba H
    Int J Clin Pharmacol Ther; 2020 Dec; 58(12):703-708. PubMed ID: 32831163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience.
    Scioscia G; Tondo P; Nolasco S; Pelaia C; Carpagnano GE; Caiaffa MF; Valenti G; Maglio A; Papia F; Triggiani M; Crimi N; Pelaia G; Vatrella A; Foschino Barbaro MP; Crimi C
    J Clin Med; 2023 Jun; 12(13):. PubMed ID: 37445397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis.
    Iftikhar IH; Schimmel M; Bender W; Swenson C; Amrol D
    Lung; 2018 Oct; 196(5):517-530. PubMed ID: 30167841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Benralizumab: A New Approach for the Treatment of Severe Eosinophilic Asthma.
    Dávila González I; Moreno Benítez F; Quirce S
    J Investig Allergol Clin Immunol; 2019 Apr; 29(2):84-93. PubMed ID: 31017107
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma.
    Matera MG; Calzetta L; Rinaldi B; Cazzola M
    Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):1007-1013. PubMed ID: 28737051
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience.
    Emma R; Morjaria JB; Fuochi V; Polosa R; Caruso M
    Ther Adv Respir Dis; 2018; 12():1753466618808490. PubMed ID: 30354852
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of distinct phenotypes related to benralizumab responsiveness in patients with severe eosinophilic asthma.
    Yamada H; Nakajima M; Matsuyama M; Morishima Y; Arai N; Hida N; Nakaizumi T; Masuko H; Yatagai Y; Saito T; Hizawa N
    PLoS One; 2021; 16(3):e0248305. PubMed ID: 33705484
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
    Castro M; Wenzel SE; Bleecker ER; Pizzichini E; Kuna P; Busse WW; Gossage DL; Ward CK; Wu Y; Wang B; Khatry DB; van der Merwe R; Kolbeck R; Molfino NA; Raible DG
    Lancet Respir Med; 2014 Nov; 2(11):879-890. PubMed ID: 25306557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy.
    Bakakos A; Rovina N; Bakakos P
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-Term Treatment With Anti-Interleukin 5 Antibodies in a Patient with Chronic Eosinophilic Pneumonia.
    Shimizu Y; Kurosawa M; Sutoh Y; Sutoh E
    J Investig Allergol Clin Immunol; 2020 Apr; 30(2):154-155. PubMed ID: 31778113
    [No Abstract]   [Full Text] [Related]  

  • 32. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
    Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
    Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases.
    Sridhar S; Liu H; Pham TH; Damera G; Newbold P
    Respir Res; 2019 Jan; 20(1):14. PubMed ID: 30658649
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype.
    Pelaia C; Crimi C; Pelaia G; Nolasco S; Campisi R; Heffler E; Valenti G; Crimi N
    Clin Exp Allergy; 2020 Jul; 50(7):780-788. PubMed ID: 32347992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rapid and Consistent Improvements in Morning PEF in Patients with Severe Eosinophilic Asthma Treated with Mepolizumab.
    Ortega H; Menzies-Gow A; Llanos JP; Forshag M; Albers F; Gunsoy N; Bradford ES; Yancey SW; Kraft M
    Adv Ther; 2018 Jul; 35(7):1059-1068. PubMed ID: 29949045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials.
    Cabon Y; Molinari N; Marin G; Vachier I; Gamez AS; Chanez P; Bourdin A
    Clin Exp Allergy; 2017 Jan; 47(1):129-138. PubMed ID: 27859832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Matching-adjusted indirect comparison of benralizumab
    Bourdin A; Husereau D; Molinari N; Golam S; Siddiqui MK; Lindner L; Xu X
    Eur Respir J; 2018 Nov; 52(5):. PubMed ID: 30309978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting IL-5 pathway against airway hyperresponsiveness: A comparison between benralizumab and mepolizumab.
    Calzetta L; Ritondo BL; Matera MG; Facciolo F; Rogliani P
    Br J Pharmacol; 2020 Oct; 177(20):4750-4765. PubMed ID: 32857420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Severe Eosinophilic Allergic Asthma Responsive to Mepolizumab After Failure of 2 Consecutive Biologics.
    Sánchez-Jareño M; Barranco P; Romero D; Domínguez-Ortega J; Quirce S
    J Investig Allergol Clin Immunol; 2019 Feb; 29(1):79-81. PubMed ID: 30785114
    [No Abstract]   [Full Text] [Related]  

  • 40. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Ferguson GT; FitzGerald JM; Bleecker ER; Laviolette M; Bernstein D; LaForce C; Mansfield L; Barker P; Wu Y; Jison M; Goldman M;
    Lancet Respir Med; 2017 Jul; 5(7):568-576. PubMed ID: 28545978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.